RT Journal Article
SR Electronic
T1 COVID19 vaccine type and humoral immune response in patients receiving dialysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.02.21261516
DO 10.1101/2021.08.02.21261516
A1 Pablo Garcia
A1 Shuchi Anand
A1 Jialin Han
A1 Maria Montez-Rath
A1 Sumi Sun
A1 Tiffany Shang
A1 Julie Parsonnet
A1 Glenn M Chertow
A1 Brigitte Schiller
A1 Graham Abra
YR 2021
UL http://medrxiv.org/content/early/2021/08/04/2021.08.02.21261516.abstract
AB Background Patients on dialysis vaccinated with the attenuated adenovirus SARS-CoV-2 vaccine might mount an impaired response to vaccination.Methods We evaluated the humoral vaccination response among 2,099 fully vaccinated patients receiving dialysis. We used commercially available assays (Siemens) to assess prevalence of no response or diminished response to COVID-19 vaccination by vaccine type. We defined “no seroconversion” as lack of change from negative to positive in total RBD Ig antibody, no detectable response on semiquantitative RBD IgG antibody (index value <1) as “no RBD IgG response”, and a semiquantitative RBD IgG index value <10 as “diminished RBD IgG response”Results Of the 2,099 fully vaccinated patients on dialysis, the proportion receiving the mRNA1273, BNT162b2, and Ad26.COV2.S were 62% (n=1316), 20% (n=416) and 18% (n=367), respectively. A third (33.3%) of patients receiving the attenuated adenovirus Ad26.COV2.S vaccine failed to seroconvert and an additional 36% had no detectable or diminished IgG response even 28-60 days post vaccination.Conclusion One in three fully vaccinated patients receiving dialysis had evidence of an impaired immune response to the attenuated adenovirus Ad26.COV2.S vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Garcia was funded by the American Kidney Fund Clinical Scientist in Nephrology Award and the Stanford University School of Medicine Leeds Compassionate Scholar Award. Dr. Anand was supported by R01DK127138. Dr Chertow was supported by K24DK085446.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at Stanford University reviewed and approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data will be reviewed by the authors, and data made available on a case-by-case basis.